#United States #Las Vegas #VIVA Foundation #Vascular Medicine #VEINS

Vascular Innovation on Display: VIVA Foundation at VEINS and VIVA 2025

The VIVA Foundation is poised to present significant new data in the realm of vascular medicine from November 1 to November 4, 2025, during The VEINS and VIVA conferences at Wynn Las Vegas. With a legacy of over two decades in showcasing transformative and practice-altering findings, VIVA (Vascular InterVentional Advances) has built a reputation as a cornerstone for education and advancement in peripheral vascular diseases.

The 2025 conference will witness results from 23 critical clinical trials, providing attendees with a unique opportunity to engage with pioneering research and innovation within vascular care. This platform not only highlights groundbreaking trial data but also integrates a variety of educational methodologies, including live case presentations, interactive workshops, and discussions led by an esteemed international faculty.

In conjunction with VIVA, the VEINS (Venous Endovascular INterventional Strategies) conference complements this initiative by honing in on the challenges associated with the diagnosis and management of venous disorders. It's an educational arena that spans the full spectrum of vascular care, designed to address both common and complex conditions effectively.

The event promises a collaborative spirit. Attendees can anticipate an exchange of ideas that draws from extensive global expertise in vascular intervention. Clinical leaders from diverse medical fields will come together to share insights and practical applications derived from the latest studies. This fosters a collegial environment, evident in the structure of the sessions themselves where participants are encouraged to engage and deliberate actively.

The agenda for the VEINS and VIVA conferences encompasses a variety of seminal clinical trial outcomes, each presenting valuable findings that could redefine patient treatment pathways. Highlights of the trials from the VEINS conference include:

• - A randomized comparison of cyanoacrylate closure versus endothermal ablation focusing on performance metrics through the first 12 months.
• - Safety evaluations of innovative devices for treating chronic venous insufficiency, further enriching the discourse around state-of-the-art treatment methodologies.
• - Outcomes related to the efficacy of thrombolytic approaches for pulmonary embolism, showcasing a direct assessment of cost-effectiveness and functional recovery prospects.

Moreover, the VIVA side demonstrates significant advancements, such as prolonged efficacy studies of drug-eluting devices and novel technologies aimed at improving patient outcomes in critical limb threatening ischemia, with several trials shedding light on innovative therapeutics and their application across varying vascular conditions.

Media representatives and health professionals from various sectors are invited to participate either in person or via online platforms, ensuring widespread dissemination and discussion of this important data. For press registration, interested parties can reach out via provided contact methods and can explore the comprehensive agenda available on the VIVA Foundation's official website.

In summary, The VEINS and VIVA 2025 conferences stand as a testament to perseverance and innovation within vascular medicine, calling upon healthcare professionals, researchers, and educators to come together and explore new frontiers within the field. Attendees will not only gain insights from the trial presentations but will also be equipped to implement these findings in their respective practices, ultimately leading to improved patient care and long-term health outcomes. As vascular medicine continues to evolve, the VIVA Foundation reaffirms its commitment to leading the charge in education and innovation, fostering an environment where collaboration and excellence thrive.